Fesoterodine Fumarate

CHEMBL1201765 Phase 4 Одобрено Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
527.6 g/mol
LogP
Phase
4

This fumarate salt form of fesoterodine is used to treat overactive bladder by blocking the nerve signals that cause sudden, uncontrollable urges to urinate. It is the active form delivered in extended-release tablets to provide consistent symptom control throughout the day.

Молекулярная масса

527,6000 g/mol

TPSA

124,00 Ų

Механизм действия

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Механизм

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

2D Структура

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)C(=O)Oc1ccc(CO)cc1[C@H](CCN(C(C)C)C(C)C)c1ccccc1.O=C(O)/C=C/C(=O)O

InChI

InChI=1S/C26H37NO3.C4H4O4/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6;5-3(6)1-2-4(7)8/h7-13,16,18-20,23,28H,14-15,17H2,1-6H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t23-;/m1./s1

Molecular Formula

C30H41NO7

HBD / HBA

3 / 8

Вращаемые Связи

13

Тяжёлые Атомы

38

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

This fumarate salt form of fesoterodine is used to treat overactive bladder by blocking the nerve signals that cause sudden, uncontrollable urges to urinate. It is the active form delivered in extended-release tablets to provide consistent symptom control throughout the day.

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Yes, Fesoterodine Fumarate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201765. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 9849808. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.